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Abstract: Nifedipine is a dihydropyridine calcium-channel blocker (CCB) introduced 
approximately 30 years ago for the prophylaxis of angina symptoms, and then later utilized as 
an anti-hypertensive agent. In the 1990s, several meta-analyses and a case-control study were 
published which raised concern regarding increased mortality and increased risk for myocardial 
infarction with short-acting nifedipine. Further evaluation of these meta-analyses and case control 
study underscores some important limitations and the need to further elucidate the role of this 
class of medications in high-risk patients. Until 2000, there was a paucity of data on the long-term 
effects as well as the long-term outcomes of CCBs in the treatment of stable coronary disease or 
in patients with manifestations of the disease such as hypertension or angina. While it has been 
well established that nifedipine and other dihydropyridines lower blood pressure and improve 
symptoms of angina, several studies were designed to evaluate the effect of dihydropyridines 
on “hard” outcomes, specifically cardiovascular and cerebrovascular events. In this review, we 
describe the clinical studies evaluating the use of nifedipine when compared to placebo as well as 
other anti-hypertensive therapies in an attempt to identify the most appropriate place in therapy 
for this class of medications and to further clarify its utilization in high-risk patients.
Keywords: nifedipine, dihydropyridine, ACTION, calcium-channel blocker, coronary heart 
disease, hypertension
In 2004, one of every five deaths in the United States was caused by coronary heart 
disease (CHD).1 It is the single largest killer of Americans, with one coronary event 
occurring every 26 seconds and one death every minute as a result.1 Estimated direct 
and indirect costs of CHD in the United States for 2008 is approximately US$156.4 
billion.1 Globally, the leading causes of death are ischemic heart disease (12.2% of 
all deaths) and cerebrovascular conditions (9.7% of all deaths), as they caused almost 
32% of all deaths in women and 27% in men in 2004.2 Hypertension is considered one 
of the major risk factors in the development of cardiovascular (CV) disease as 69% of 
people with first heart attack, 77% with first stroke, and 74% with heart failure have 
blood pressure higher than 140/90 mmHg.1 Thus, controlling hypertension should help 
lead to a reduction in morbidity and mortality. However, does blood pressure control 
alone help to improve cardiac outcomes, or do certain blood pressure lowering drugs 
innately provide more benefit than others?
In the Heart Outcomes Prevention Evaluation Study (HOPE), while ramipril 
induced only a modest decrease in blood pressure (by 3.3 mmHg/1.4 mmHg) in 
high-risk, mostly normotensive patients, there was a reduction in the primary endpoint Vascular Health and Risk Management 2009:5 430
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[CV death, myocardial infarction (MI), stroke] over 4.5 years 
by 22%.3 It is suggested that protective actions on left ven-
tricular hypertrophy, endothelial function, and smooth mus-
cle growth afforded by an angiotensin-converting enzyme 
inhibitor (ACE-I) help explain this phenomenon.4 However, 
questions arose about blood pressure reductions being under-
estimated since ramipril was given once daily at bedtime and 
blood pressure was measured during the day. Svensson et al 
conducted a substudy of the HOPE trial to assess the effect of 
ramipril on 24-hour blood pressure.5 Although office blood 
pressures or day ambulatory blood pressures (ABP) were not 
significantly reduced after 1 year, this substudy found that 
night and 24-hour ABP readings were significantly reduced 
during treatment with ramipril 10 mg once daily at bedtime 
compared with placebo (by 17 mmHg/8 mmHg, p  0.001 
and by 10 mmHg/4 mmHg, p = 0.03, respectively). The 
authors concluded that the effects seen on cardiovascular 
morbidity and mortality with ramipril may be related on 
blood pressure patterns over the 24-hour period.5
Freemantle et al conducted a systematic review of 82 ran-
domized, controlled trials and reported a 23% mortality 
reduction after long term utilization of beta-blockers (BBs) 
in patients that have suffered from an MI.6 Whether reducing 
the proarrhythmic effects of antiarrhythmic agents on board 
or providing anti-ischemic benefit for angina patients through 
their negative chronotropic and negative inotropic properties, 
it is recommended that BB therapy be initiated immediately in 
all post-MI patients and continued indefinitely for secondary 
prevention of MI and death.7–9 According to the Seventh 
Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure 
for treatment of hypertension (JNC 7), BBs are only indicated 
as first-line therapy in patients with compelling indications 
such as stable/unstable angina, heart failure, and non-ST 
segment elevated MI.10 These guidelines are consistent with 
the 2007 guidelines for the management of hypertension 
from the European Society of Hypertension (ESH) and the 
European Society of Cardiology (ESC).11 However, with 
respect to primary prevention, several meta-analyses warn 
that BBs may not provide as much CV event reduction as 
other antihypertensives, especially in patients older than 
60 years of age, and therefore are not recommended as first-
line therapy for hypertension in these patients.12,13
The antihypertensive and lipid-lowering treatment to 
prevent heart attack trial (ALLHAT) showed that drug 
therapy started with a dihydropyridine (DHP) calcium 
channel blocker (CCB), an ACE-I, or a thiazide diuretic did 
not differ in the primary endpoint of combined fatal CHD and 
non-fatal MI.14 Given ample data for a reduction in morbidity 
and mortality, low cost, and relative good tolerability, thiazide 
diuretics are recommended as the preferred initial agent in 
hypertensive patients without any compelling indications.10 
Beta-blockers, CCBs, ACE-I, and angiotensin II receptor 
blockers (ARBs) are recommended as add-on therapy if 
blood pressure remains elevated on thiazide monotherapy.10 
The JNC 7 does recommend long-acting DHP or non-DHP 
CCBs if angina and blood pressure are not controlled by BB 
therapy alone, or when BBs are contraindicated.10 Although 
CCBs are useful in the management of angina, there is no 
consensus about their role in preventing CV events in patients 
with established coronary artery disease (CAD).15 The 2007 
AHA Scientific Statement on treatment of hypertension in 
the prevention and management of ischemic heart disease 
takes a more comprehensive approach and recommends an 
ACE-I, ARB, CCB, thiazide diuretic, or a combination of 
those agents.15 The authors recognize the controversy over 
drug choice, but support this recommendation by stating 
that the amount of blood pressure reduction, rather than the 
choice of antihypertensive agent, is the major determinant 
in reduction of CV risk.15 Likewise, the 2007 ESH/ESC 
guidelines for the management of hypertension also state 
that the main benefits of antihypertensive treatment are 
due to lowering blood pressure and are independent of the 
agent that is chosen.11 In addition, the ESH/ESC guidelines 
specify that any of the five classes of antihypertensive agents 
(ACE-Is, ARBs, thiazides, CCBs, or BBs) are appropriate as 
initial or maintenance therapy.11 Clinicians aim to provide 
an anti-hypertensive that will provide the most benefit with 
regard to reducing a patient’s risk for CV events. Aside from 
pure antihypertensive effect and symptomatic improvement 
in angina, is there data to recommend consideration of CCBs 
prior to use of ACE-I or thiazides in these high-risk patients 
with CAD? For the purpose of this manuscript, we will focus 
on the use of nifedipine and also present supporting evidence 
of other DHP CCBs in the treatment of high-risk patients 
with coronary artery disease and hypertension, evaluating 
impact on morbidity and mortality.
Nifedipine is a DHP CCB that was introduced 30 years 
ago.16 It was initially developed for the prophylaxis of angina 
symptoms, and then later utilized as an anti-hypertensive 
agent.17 Nifedipine acts by inhibiting the trans-membrane 
influx of calcium into cardiac and vascular smooth muscle 
cells, thus reducing muscle contraction and has predomi-
nantly vasodilatory effects on arteries with minimal effects 
on the myocardium and cardiac conduction.16 The nife-
dipine gastrointestinal therapeutic system (GITS) tablet is Vascular Health and Risk Management 2009:5 431
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based on an osmotic pump that releases nifedipine through 
a laser-drilled hole in an inert shell at a controlled rate.18 
This ensures that drug release is uniform over a 24-hour 
period with a trough: peak ratio approaching 1, therefore 
maintaining blood pressure control throughout the dosing 
period. This smooth reduction in blood pressure does not 
result in sympathetic stimulation, and there is no increase in 
heart rate as seen with short-acting formulations or some of 
the longer acting generic versions of nifedipine.19
Antiatherosclerotic effects of CCBs have been observed 
in animal studies and in experiments using human cultured 
cells. This is thought to be mediated by many factors, 
including antioxidant activity and enhancement of nitric 
oxide production.20 Most of these effects require a much 
higher dose than usual clinical doses, but it has been reported 
that some CCBs can inhibit atherosclerosis even at clinical 
doses.21–24
In the 1990s, several meta-analyses and a case-control 
study that were published raised concern about increased 
mortality and increased risk for MI with short-acting 
nifedipine.25,26 Authors suggested that the reflex increase in 
sympathetic activity induced by short-acting CCBs may be 
the underlying mechanism of action behind observed proisch-
emic, negative inotropic, and arrhythmogenic effects of these 
drugs.26 Although immediate release formulations of CCBs 
were approved only for treatment of vasospastic angina, 
they were prescribed historically to many patients as an 
anti-hypertensive as well. Further evaluation of these meta-
analyses and case control study highlight many limitations 
including indication bias in the case-control study, as well 
as multiple inaccuracies in the Furberg analysis, which may 
lead to a different conclusion altogether.27,28 At present, there 
is no indication for short-acting CCB therapy. Long-acting 
CCBs have not been shown to increase mortality or risk for 
MI, and are commonly used anti-hypertensive medications 
in elderly subjects since they are well tolerated and effective. 
Over the past 10 years, more data demonstrating their efficacy 
in decreasing the incidence of CV events in long-term clinical 
trials have become available.
In 1996, Gong et al conducted a single-blind trial to 
assess the effectiveness of nifedipine 10 mg twice a day 
(with an increase to 60 mg daily to reach the desired 
blood pressure level) in elderly hypertensives over an 
average follow-up period of 2.5 years.29 This trial, the 
Shanghai trial of nifedipine in the elderly study (STONE), 
included 1632 patients, ages 60 to 79 years with a systolic 
blood pressure (SBP) 160 mmHg or diastolic blood pressure 
(DBP) 96 mmHg. Additional medications were permissible 
if needed to get BP to goal (captopril 20 to 50 mg/day and/or 
dihydrochlorothiazide 25 mg/day). The endpoints of the 
study were combined CV events (stroke, heart failure, MI, 
and severe arrhythmia, and sudden death), non-CV events 
(malignancy, others), and all deaths. The relative risk for 
combined CV events was significantly reduced by 62% 
(p = 0.0001), with the greatest contribution coming from 
reductions in risk of stroke and severe arrhythmias. There 
was, however, no significant difference in relative risk of 
death (p = 0.0614). Overall, 65% of subjects in the nifedipine 
group attained the blood pressure goal of 160/90 mmHg. 
A significant difference between the placebo group’s SBP and 
the nifedipine group’s SBP was found after only 6 months 
(p = 0.0017), whereas the DBP difference was evident after 
1 year (p = 0.0113). Initial assignment into the two groups 
(placebo and nifedipine), yielded highly comparable risk 
factors such as age, cholesterol, body mass index (BMI), 
triglycerides, glycemia, abnormalities of fundi, smoking, 
and alcohol consumption.
Undoubtedly, the single-blinded design is a limitation 
of the STONE study. In addition, 74 subjects were allowed 
to be reallocated from placebo to active treatment because 
their DBP was 110 mmHg. Another limitation could be that 
this study was conducted in the Chinese population where 
it has been demonstrated that MI is much less frequent than 
strokes in the People’s Republic of China,30 but the authors 
did state that the population appeared to have predictors of 
clinical events (other than MI) similar to those of other ethnic 
groups, including the Framingham population and other 
Caucasians. Nifedipine retard (a long-acting formulation) 
significantly reduced the risk of major clinical events 
compared with placebo in elderly hypertensive patients in 
the STONE study. More recently, nifedipine retard was used 
in the Japan Multicenter Investigation for CV Diseases-B 
(JMIC-B) study and had similar efficacy to ACE-I therapy, 
in terms of reducing major cardiac events in patients with 
both hypertension and CAD.31
Data from Pristipino et al show that acetylcholine loading 
brought about a three-fold higher incidence of coronary spasm 
among Japanese patients than among Caucasian patients after 
MI.32 As a result, CCBs have been widely used in Japan 
for coronary artery disease and hypertension. In 2000, the 
Japanese Society of Hypertension Guidelines Subcommit-
tee for the Management of Hypertension recommended 
CCBs for blood pressure control in hypertensive patients 
with angina pectoris, and ACE-Is in hypertensive patients 
with a history of MI.33 The JMIC-B compared these two 
agents to see which could better prevent cardiac events in Vascular Health and Risk Management 2009:5 432
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hypertensive patients with CAD.31 This was a multi-centered 
prospective randomized open trial with blinded-endpoint 
evaluation (PROBE) that randomized 1650 patients, 75 years 
or younger, to 3 years of treatment with nifedipine or 
ACE-I. Blood pressure before antihypertensive treatment 
for all enrolled patients was SBP  150 and DBP  90. 
Ninety-two percent of participants had previously received 
antihypertensive treatment and were switched to the study 
drug without any washout period. Exclusion criteria included 
DBP  120 mmHg, secondary hypertension, symptomatic 
cerebrovascular disease, overt heart failure, atrial fibrilla-
tion, ventricular tachycardia/ventricular fibrillation, severe 
renal/hepatic dysfunction, uncontrolled diabetes mellitus, and 
familial hypercholesterolemia. Long-acting nifedipine given 
at a dose of 10 to 20 mg twice daily was compared against 
enalapril 5 to 10 mg, imidapril 5 to 10 mg, or lisinopril 10 to 
20 mg once daily. Treatment aimed to lower SBP to less than 
150 mmHg and DBP to less than 90 mmHg. If target not 
met with monotherapy, then an alpha-blocker (doxazosin, 
bunazosin or prazosin) was administered concomitantly. 
If angina persisted on monotherapy, then long-acting or 
short-acting nitrates and/or beta-blockers were used con-
comitantly.
In  previously  treated  patients,  the  mean  blood 
pressure (SBP/DBP) before starting treatment was 
167 ± 20/93 ± 13 mmHg and 165 ± 20/93 ± 13 mmHg 
in the nifedipine group and ACE-I group, respectively. 
However, their baseline blood pressures before switching 
to the study drug were 146 ± 17/81 ± 11 mmHg and 144 ± 
19/81 ± 12 mmHg in the nifedipine group and ACE-I group, 
respectively (no significant difference), while the blood 
pressure in the untreated patients were 160 ± 25/91 ± 
14 mmHg and 163 ± 21/93 ± 13 mmHg in the nifedipine 
group and ACE inhibitor group, respectively (no significant 
difference). The fact that 92% of patients had already been 
taking antihypertensives (which included CCBs, ACE-Is, 
alpha-blockers, BBs, and diuretics) leads readers to question 
the strength of this study. These previously treated patients 
had a relatively well-controlled blood pressure before being 
switched to study drugs and there was no mention of average 
duration of treatment prior to initiation of study drugs. It is 
reasonable to question the effect of this study design on the 
results of the study.
At the end of treatment, the mean dose of nifedipine 
was  31.9  ±  10.7  mg/day,  while  that  of  enalapril 
was 5.6 ± 2.5 mg/day, lisinopril was 10.2 ± 3.9 mg/day, and 
imidapril was 6.8 ± 2.4 mg/day. The mean reduction of blood 
pressure (SBP/DBP) was 11/5 mmHg in the nifedipine 
group and 7/4 mmHg in the ACE-I group (p  0.01). The 
percentage of patients who received concomitant therapy with 
ACE-I, nitrates, and BBs were equivalent in both treatment 
groups. However, the difference in rate of alpha-blocker was 
statistically significant (6.3% in CCB group and 10.7% in 
ACE-I group, p  0.0012). A subgroup analysis showed that 
alpha-blocker use had no significant impact on incidence of 
cardiac events. The primary endpoint was the overall inci-
dence of cardiac events (cardiac death or sudden death, MI, 
hospitalization for angina pectoris or heart failure, serious 
arrhythmia, and coronary interventions). The primary endpoint 
occurred in 116 patients (14.0%) in the nifedipine retard group 
and 106 patients (12.9%) in the ACE-I group. There was no 
significant difference between the two groups (p = 0.75).
In the CCB group, patients with a history of MI had a 
reduction in the risk of hospitalization for angina pectoris of 
58% when compared with the ACE-I group. The antispastic 
effect of this drug on the coronary arteries may likely be a 
factor leading to the reduced incidence of hospitalization 
for angina pectoris in post-MI patients. Authors highlight 
that baseline and end of study blood pressure of patients in 
the JMIC-B study were comparable to those of patients in 
ALLHAT. Blood pressure was well-controlled in both trials, 
and may explain consistency in results between JMIC-B 
and ALLHAT.14,31 Upon review of dosage regimens used 
in this study, the doses seemed inadequate when compared 
to doses used in Americans and Europeans. However, these 
dose levels are considered optimum for efficacy and safety 
in Japanese patients, and standard doses of these ACE-Is 
were determined in multi-center clinical studies based on 
the Japanese guidelines for evaluating antihypertensive 
drugs.34–37 The effects of nifedipine on the progression 
of coronary atherosclerosis were compared with those of 
ACE-Is using quantitative coronary angiogram (QCA) of 
the CV measurement system in a JMIC-B side arm study.38 
Seventy-seven institutions specializing in CV diseases agreed 
to submit coronary angiogram films of patients to the core 
angiographic laboratory before and 36 months after the 
start of treatment. Study analyses were performed on the 
data from 83 and 79 patients in the nifedipine and ACE-I 
groups, respectively. These analyses showed that nifedip-
ine was better than ACE-Is in inhibiting the progression of 
coronary atherosclerosis and in the reduction of development 
of new lesions. Despite the effects on atherosclerosis based 
on QCA, clinically this did not translate into a reduction of 
morbidity and there were no significant differences that were 
found in the incidence of cardiac events between the groups 
(nifedipine 25 patients; ACE-I 22 patients).Vascular Health and Risk Management 2009:5 433
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In recent years, a couple of key clinical trials have 
expanded the body of evidence available on modified-release 
formulations of nifedipine. The International Nifedipine 
GITS study: Intervention as a Goal in Hypertension 
Treatment (INSIGHT) was the first, large, double-blind, 
randomized trial undertaken exclusively in high-risk hyper-
tensive patients, with CV events as a prospectively defined 
primary end-point.39 This trial compared the effects of 
nifedipine GITS 30 mg daily with co-amilozide 25/2.5 mg 
daily (combination of hydrochlorothiazide and amiloride) 
on CV mortality and morbidity in 6321 patients aged 55 to 
80 years old from Europe and Israel. This study consisted 
of hypertensive patients (blood pressure 150/95 mmHg, 
or SBP  160 mmHg) with an additional risk factor which 
included hyperlipidemia, smoker, family history of MI in 
parent or sibling 50 years old, left ventricular hypertrophy, 
CHD, left ventricular strain, peripheral vascular disease, 
or proteinuria. Dose doubling and additional therapy with 
atenolol 25 mg daily or enalapril 5 mg daily was allowed if 
BP was 140/90 mmHg after 2 weeks of treatment.
The primary outcome (CV death, MI, heart failure, and 
death) occurred in 200 (6.3%) patients in the nifedipine group 
compared to 182 (5.8%) in the co-amilozide group. These 
findings were not significant (p = 0.35) and showed that once 
daily nifedipine was equally effective as co-amilozide in 
preventing overall CV or cerebrovascular complications over 
a mean follow-up of 4 years. Mean BP fell by 33/17 mmHg 
and remained close to 138/82 mmHg in both groups (also 
no difference between the groups). Demography and 
distribution of risk factors did not differ significantly between 
the treatment groups. Event rates were higher in some risk 
groups than others and most did significantly affect outcomes 
(smoking, previous MI, proteinuria, sex, and age), but there 
were no apparent differences between the two treatment 
groups. The authors reported 1259 patients received atenolol 
and 756 patients received enalapril as add on treatment, with 
a similar fall in blood pressure, but neglected to mention any 
possible influence that these additional drugs may have had on 
the outcome. When considering vascular function, substudies 
of INSIGHT showed that nifedipine GITS compared with 
diuretic therapy, slowed the progression of carotid intima-
media thickening and coronary calcification, and improved 
endothelial function in patients with CV disease.40 However, 
this has yet to be demonstrated to be clinically important.
Clinical trials such as INSIGHT have indicated that 
nifedipine GITS significantly lowers blood pressure while 
reducing CV risk, in addition to being effective and safe in 
a broad spectrum of patients. Similar results were observed 
with amlodipine in the ALLHAT trial which showed a 
lower incidence of stroke, combined CV disease, angina and 
peripheral arterial disease when compared with lisinopril.14 
Nifedipine and other DHP CCBs have also been studied 
extensively in the treatment of angina pectoris. The majority 
of these studies were designed to assess symptomatic 
improvement defined as a reduction in angina symptoms. 
However, until 2004, there was a paucity of data about the 
long-term effects as well as the long-term outcomes of CCBs 
in the treatment of stable coronary disease or in patients 
with manifestations of the disease such as hypertension or 
angina.
A coronary disease trial investigating outcome with 
nifedipine GITS (ACTION) was one of the largest studies 
designed to evaluate the effect of long-acting nifedipine 
GITS on mortality and CV morbidity in patients with 
stable angina requiring treatment.41 This was a randomized, 
placebo controlled, double-blinded trial, (planned duration 
4.5 to 6 years) in which 6084 men and 581 women were 
recruited by 291 centers from 19 countries. Patients were eli-
gible for the study if they were 35 years of age and older, had 
stable angina pectoris for at least one month, required therapy 
to prevent symptoms, and either had a history of MI, CAD 
confirmed by angiography, or had a positive exercise test or 
perfusion defect. Exclusion criteria consisted of orthostatic 
hypotension (or DBP  90 mmHg), SBP  200 mmHg 
or DBP  105 mmHg, and patients with left ventricular 
ejection fraction 40%. Patients were randomly assigned 
to nifedipine GITS (n = 3825) 30 to 60 mg daily or matched 
placebo (n = 3840) in addition to the basic regimen the patient 
was taking. During the study, providers were permitted to 
treat symptomatic patients with conventional drugs. The 
primary efficacy outcome was major CV event-free survival 
defined as death from any cause, acute MI, refractory angina, 
new overt heart failure, debilitating stroke, and peripheral 
revascularization. The primary combined safety outcome 
included death from any cause, acute MI, and debilitating 
stroke. Secondary outcomes included any CV event, any 
death, any CV event or procedure, and any vascular event 
or procedure. The mean follow up of this trial was 4.9 years. 
Mean baseline blood pressure measurement in both groups 
was approximately 137/80 mmHg. However, 50% of the 
population has a blood pressure 140/90 at baseline.
There was no statistically significant difference with 
regard to the primary efficacy outcome between nifedipine 
GITS and placebo (hazard ratio 0.97 [95% CI 0.88–1.07], 
p = 0.54). When the incidence of clinical events was 
evaluated separately, new overt heart failure was the only Vascular Health and Risk Management 2009:5 434
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component of the primary endpoint that reached statistical 
significance favoring nifedipine (29% reduction, p = 0.015). 
However, nifedipine GITS did show a benefit with regard 
to a reduction in the need for coronary procedures and 
symptom interventions. Coronary angiography was reduced 
by 18% (p  0.0001) and coronary artery bypass grafting 
was reduced by 21% (p = 0.002). There were no statistically 
significant differences in the rates of MI between nifedipine 
GITS compared to placebo (hazard ratio 1.04 [95% CI 
0.88–1.24], p = 0.62), and this information, in part, dispels 
past controversies pertaining to an increased risk of MI with 
other formulations of nifedipine.
While it is well established that a reduction in blood 
pressure translates to a reduction in CV events, it is of 
interest that despite a mean reduction in a blood pressure 
of 3.9/2.4 mmHg in normotensive patients in the ACTION 
trial, this did not translate to a reduction in the primary 
outcome. A large percentage of patients in the ACTION trial 
were receiving medications that are well established in risk 
reduction such as statins, BBs, and aspirin. This potentially 
makes additional benefit more difficult to achieve.
However, in the ACTION trial, 52% of patients 
were hypertensive at baseline (defined as blood pressure 
of 140/90). Keeping in mind that some patients designated 
as “normotensive” at baseline, quite possibly had controlled 
hypertension as this definition was irrespective of treatment. 
In the predefined subgroup of patients with hypertension, 
there was a statistically significant reduction of 13% in the 
primary combined endpoint of death from any cause, acute 
MI, refractory angina, new overt heart failure, debilitating 
stroke, and peripheral revascularization. However, when 
evaluated separately, new overt heart failure and debilitat-
ing stroke were the only components to reach statistical 
significance. Therefore, in patients with CAD and hyperten-
sion, nifedipine GITS may be beneficial as add-on therapy as 
the design of ACTION did not include a washout period, and 
as previously mentioned a high percentage of patients were 
already receiving therapies proven to reduce CV risk.
The INSIGHT and ACTION trials, along with the 
STONE and JMIC-B trial, provide evidence that long acting 
nifedipine can be used safely in high-risk, elderly patients to 
lower blood pressure and possibly improve clinical outcomes 
(Table 1).29,31,39,41 Nifedipine has not been proven inferior to 
other therapies and in fact may provide benefit with regard 
to reductions in hospitalizations as well as CV procedures. 
However, the role of nifedipine GITS as first-line therapy 
or as monotherapy in high-risk patients needs to be further 
elucidated.
The above trials examined the use of nifedipine and its 
impact on the risk of CV events, however one must also 
consider clinical trials involving other DHP CCBs, as they 
may provide more insight for use of this agent in the treatment 
of high risk patients with CAD and hypertension. The 
question of whether DHP CCBs have benefit beyond blood 
pressure lowering, possible benefit due to anti-anginal prop-
erties, and benefit when added to standard therapy in patients 
with CAD has been addressed in multiple clinical trials. In 
the prospective randomized evaluation of the vascular effects 
of the Norvasc (PREVENT) study, the effect of amlodipine 
on progression of coronary atherosclerosis was compared 
to placebo in 825 patients over 36 months.42 There was no 
statistically significant difference in major CV event rates 
and in the average 36-month reductions in the minimal lumen 
diameter (0.084 versus 0.095 mm; p = 0.38). Results of the 
PREVENT trial differ from that of the JMIC-B Side Arm 
Study, which did show a suppression of the progression of 
coronary atherosclerosis.38 Shinoda et al noted the difference 
in study population and emphasize that Japanese patients with 
atherosclerosis have a higher incidence of coronary spasm 
which could aggravate atherosclerosis, thereby explain-
ing the beneficial effects of CCBs on plaque rupture and 
erosion.32,43 The NICOLE study evaluated the effect of nisol-
dipine on progression of coronary atherosclerosis.44 There 
was no statistically significant difference when compared 
to placebo. In the CAMELOT trial, there was a statistically 
significant reduction in coronary revascularizations with 
amlodipine.45 However, similar to the CAMELOT trial, 
results of the PREVENT and NICOLE studies led to fewer 
hospitalizations for unstable angina and revascularizations. 
Perhaps the possibility exists of improved symptom control 
leading to a reduction in patients seeking medical care, and 
hence hospitalizations and procedures.
However, there are some trials that raised questions 
regarding the impact of DHP CCBs on reduction of CV 
events. The fosinopril versus amlodipine cardiovascular 
events randomized trial in patients with hypertension and 
non-insulin dependent diabetes mellitus (FACET) was an 
open-labeled trial that randomized 380 hypertensive diabetics 
to fosinopril 20 mg/day or amlodipine 10 mg/day and 
followed for up to 3.5 years.46 By the end of the study, the 
SBP was 4 mmHg lower in the amlodipine group compared 
with fosinopril (p  0.01), while both groups had the same 
reduction in DBP compared with baseline (8 mmHg). Despite 
a significantly greater reduction in SBP in the CCB group, 
the proportion of patients diagnosed with the combined 
secondary end point of stroke, acute MI, or hospitalized Vascular Health and Risk Management 2009:5 435
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angina was significantly lower in the fosinopril group 
compared with amlodipine group (p = 0.030, HR = 0.49, 
95% CI = 0.26–0.95). These results raised doubts and 
highlighted the limitations of blood pressure lowering as 
a surrogate marker of clinical efficacy of antihypertensive 
therapy. However, limitations of this trial should be pointed 
out. For example, the timing of blood pressure measurement 
was likely to be close to the peak effect of amlodipine and 
to the trough effect of fosinopril possibly leading to greater 
reduction in SBP found in the CCB group than with the 
ACE-I group.47,48 In addition, Tatti suggests that the relative 
dose of amlodipine was greater than that of fosinopril, or that 
amlodipine was more effective than fosinopril in lowering 
blood pressure.46 It is also important to report that almost one 
third of the patients used combination treatment of fosinopril 
plus amlodipine, and as a result, in the intention-to-treat 
analyses, any treatment effect would be diluted. Lastly, this 
trial was open-label, conducted at a single site, and was not 
designed and powered to assess a difference between the two 
treatments in vascular events.
The results of FACET are in agreement with those of 
the Multicenter Isradipine Diuretic Atherosclerosis Study 
(MIDAS). In both trials, hypertensive patients with diabetes or 
impaired glucose metabolism who received alternative treat-
ments had a significantly lower risk of CV events, compared 
with those who received a CCB. Results of animal studies have 
demonstrated the antiatherogenic properties of isradipine as 
well as other CCBs.49–53 MIDAS compared the rate of progres-
sion of mean maximum intimal-medial thickness (IMT) in 
carotid arteries during antihypertensive therapy with isradip-
ine versus hydrochlorothiazide over 3 years.54 By 6 months, 
DBP in both groups was reduced by about 13 mm Hg from 
baseline, whereas SBP was reduced by 19.5 mmHg in the 
hydrochlorothiazide group and 16.0 mmHg in the isradipine 
group (p = 0.002). No difference was seen in the rate of 
progression of IMT between the two treatment groups over 
3 years (p = 0.68). However, there was a significant increase 
in non-major vascular events and procedures (transient 
ischemic attack, dysrhythmia, aortic valve replacement, and 
femoral popliteal bypass graft) in the isradipine group (n = 40; 
9.05%) versus the hydrochlorothiazide group (n = 23; 5.22%) 
(p = 0.02). Moreover, at the final clinic visit, 25% of the 
isradipine group and 28% of the hydrochlorothiazide group 
were taking enalapril as blood pressure was uncontrolled 
on monotherapy. Given that almost one-third of each group 
was on ACE-I therapy, this introduces a confounder and one 
must evaluate the results of this study in proper context. One 
must also notice that the rate of progression of IMT observed 
in MIDAS (0.03 mm/year) was much slower than the rate 
observed in a small pilot study of 28 untreated hyperlipidemic 
patients used to calculate the sample size of MIDAS 
(0.15–0.20 mm/year).55,56 This suggests that IMT progression 
rate may differ in different populations, and lowering blood 
pressure is not the only answer in reducing CV events. It must 
be part of a strategic plan which includes reduction of choles-
terol, diabetes control, and healthy lifestyle void of tobacco 
and full of physical activity and a healthy diet.
There were multiple studies that looked at DHP CCBs 
compared to ACE-Is, diuretics, and BBs, and provided 
evidence that DHP CCBs had similar antihypertensive 
efficacies and CV event rates similar to these classes. The 
Swedish Trial in Old Patients with Hypertension-2 study 
(STOP-2) compared the effects of conventional therapy 
(atenolol 50 mg, metoprolol 100 mg, pindolol 5 mg, or 
hydrochlorothiazide 25 mg plus amiloride 2.5 mg daily) 
with that of newer agents (enalapril 10 mg or lisinopril 
10 mg, or felodipine 2.5 mg or isradipine 2–5 mg daily) on 
CV mortality and morbidity in elderly patients.57 This trial 
showed that there were no differences in blood pressure, 
CV mortality, or major events between all the study groups 
after 4 years of follow-up. The primary combined endpoint 
of fatal stroke, fatal MI, and other fatal CV disease occurred 
in 221 of 2213 patients in the conventional (19.8 events 
per 1000 patient years) and in 438 of 4401 in newer drugs 
group (19.8 per 1000 patient years); p = 0.89. STOP-2 results 
suggested that newer antihypertensive drugs were equally 
efficacious and the choice of treatment will, therefore, 
be related to other factors such as cost, side-effects, and 
co-existing conditions.
Unlike STOP-2, the ASCOT-BPLA provided evidence 
on the contrary, and showed a DHP CCB to have better 
antihypertensive efficacy and greater reduction in CV event 
rates when compared to other agents. The Anglo-Scandinavian 
cardiac outcomes trial-blood pressure lowering arm 
(ASCOT-BPLA) was a multi-centered, prospective, random-
ized controlled trial that compared the incidence non-fatal 
MI and fatal CHD in patients on amlodipine 5 to 10 mg 
plus perindopril 4 to 8 mg versus atenolol 50 to 100 mg 
plus bendroflumethiazide 1.25 to 2.5 mg daily.58 This trial 
included patients who were mostly white men with mean age 
of 63 years old. These patients had either treated (80%) 
or untreated hypertension with an average blood pressure 
of 164/95 mmHg and at least three other cardiovascular 
risk factors which included left ventricular hypertrophy, 
type 2 diabetes, peripheral arterial disease, previous stroke 
or transient ischemic attack, male sex, age 55 and older, Vascular Health and Risk Management 2009:5 437
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microalbuminuria or proteinuria, smoking, ratio of total 
cholesterol to high-density lipoprotein cholesterol (HDL) of 
6 or higher, and family history of premature CHD. Patients 
were randomized to amlodipine adding perindopril as 
required to reach blood pressure targets or atenolol adding 
bendroflumethiazide and potassium as required. At each 
follow-up visit, drug therapy was increased to achieve target 
blood pressure of 140/90 for non-diabetics and 130/80 
for diabetic patients.
Blood pressures were lower throughout the trial in 
the amlodipine-based regimen compared with those on 
the atenolol-based regimen, with an average difference 
of 2.7/1.9 mmHg. By the end of the trial, blood pressure 
readings fell to 136.1 ± 15.4/77.4 ± 9.5 mmHg and 
137.7 ± 17.9/79.2 ± 10 mmHg in the amlodipine and 
atenolol-based regimens, respectively. It is important to note 
that by the end of the study, most patients were taking at least 
two antihypertensive agents (78%), with only 15% and 9% 
taking amlodipine and atenolol monotherapy, respectively. 
There was no statistically significant difference in primary 
endpoint of non-fatal MI plus fatal CHD when comparing 
both groups, however there were significant reductions in 
most secondary endpoints which included fatal and non-fatal 
stroke (327 versus 422; p = 0.0003), total cardiovascular 
events and procedures (1362 versus 1602; p  0.0001), 
and all-cause mortality (738 versus 820; p = 0.025). The 
trial was stopped early as those in the atenolol-based group 
had significantly higher mortality and worse outcomes on 
several secondary endpoints as mentioned above. Authors 
noted that this study was powered for 1150 patients to reach 
primary endpoint, however only 903 patients actually had 
such events because of early termination. Therefore, ASCOT 
was underpowered for the primary endpoint.
In the post-hoc analyses, which combined the primary 
endpoint plus coronary revascularizations, the event rate for 
amlodipine-based regimen was significantly reduced by 14% 
when compared to atenolol-based regimen (p = 0.0058). For 
justification of this combined endpoint, authors acknowledge 
the increase in use of interventional procedures to prevent 
future coronary events in the management of CHD, which has 
become routine clinical practice since the design of this trial. 
It was mentioned that possible explanations for differences 
in outcome in treatment groups may include higher body 
mass index, triglyceride levels, creatinine concentrations, 
and fasting blood glucose values, as well as a lower HDL 
in atenolol-based regimen group, which was found at final 
visit when compared to amlodipine-based regimen group. 
It is also important to note that about 40% of patients used 
antihypertensive agents other than those outlined in this 
study, and 8% were on four or more drugs. This study’s 
results reinforce the notion that most hypertensive patients 
need at least two drugs to reach target blood pressure. Authors 
concluded that the combination of a BB and diuretic should 
not be recommended over CCB/ACE-I for routine use, as 
the CCB/ACE-I drug regimen proved better in reduction of 
cardiovascular events and all-cause mortality.
The Systolic Hypertension in Europe Trial (Syst-Eur) 
examined whether antihypertensive therapy could reduce 
CV complications of isolated systolic hypertension.59 Active 
treatment started with nitrendipine, and if necessary, this 
drug was combined with or replaced by enalapril (up to 
20 mg daily), hydrochlorothiazide (up to 25 mg daily), or 
both. Active treatment reduced occurrence of all strokes by 
42% (p = 0.003), decreased all fatal and non-fatal cardiac 
endpoints, including sudden death, by 26% (p = 0.03), 
and reduced all fatal and non-fatal CV endpoints by 31% 
(p  0.001). Unlike the FACET or the national intervention 
cooperative study in elderly hypertensives study (NICS), the 
Syst-Eur Trial included patients that were not necessarily 
older, but sicker, as in the two treatment groups combined, 
29.9% (1402) of patients had CV complications at 
randomization. Forty-one percent (575) and 7.3% (103) 
of these patients had CHD and cerebrovascular disease, 
respectively.46,59,60 The absolute number of strokes prevented 
by active treatment was similar to that of the STOP (Swedish 
trial in old patients with hypertension) trial, and the results 
for stroke and MI were similar to that of the SHEP (systolic 
hypertension in the elderly program) trial.61,62 At the time of 
this trial, diuretics and BBs were the only antihypertensives 
used in long term clinical trials and were shown to reduce 
morbidity and mortality. This study provided some evidence 
that newer agents (CCBs and ACE-Is) also played a part in 
reducing CV complications. One may question the protec-
tive effects of CCBs alone, given that ACE-I and/or thiazide 
was added for blood pressure lowering. In response to this 
question, the Syst-Eur trial reports that the benefit of active 
treatment was seen soon after randomization when most 
patients were still on CCB monotherapy.59
Diuretics are recommended first line for the treatment of 
hypertension, however there has been a decrease in diuretic 
use and an increase in CCB use over the years. NICS aimed to 
compare the effects of a diuretic and a CCB in preventing CV 
complications in elderly hypertensive patients in Japan.60 The 
total number of CV complications during the 5-year period 
was 21 (10.3%) in the nicardipine group and 18 (8.6%) in the 
diuretic group (p = 0.923). This trial showed that nicardipine Vascular Health and Risk Management 2009:5 438
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was equivalent to trichlormethiazide in its effect against CV 
complications in elderly patients with hypertension. The 
NICS study was the first to make a direct comparison of a 
DHP CCB and a diuretic. Unlike SHEP, STOP, STONE, 
or Syst-EUR trial, this study was not a placebo-controlled 
trial, as a placebo comparison was ruled out by the steering 
committee because of ethical considerations based on the 
known efficacy of diuretics.29,59–62 In the MIDAS study, there 
was a trend toward increased incidence of vascular events 
in patients treated with CCB compared with diuretic (5.65% 
vs 3.17%, respectively; p = 0.07).54 Authors suggest that 
reasons contributing to the difference between these results 
and those of the NICS study may be the greater decrease in 
SBP in the diuretic group versus isradipine group in MIDAS 
(19.5 mmHg vs 16 mmHg, respectively; p = 0.002).
Given the fact that this study was conducted in Japan, 
one may question the population validity of these results. 
One may also question the direct comparison between these 
agents and the incidence of CV complications given that 
these complications are affected by patient age, sex, blood 
pressure, and atherosclerotic complications before the study. 
However, the CV complication rate per 1000 persons per 
year in the treated groups was 21 in the MRC (medical 
research council trial of treatment of hypertension in 
older adults) study, 33.5 in the STOP study, 23.3 in the 
Syst-Eur study, 21.4 in the Syst-China study, and 27.8 in 
the nicardipine group and 26.8 in the diuretic group in the 
NICS study.59–61,63,64 The similarities with the values from 
these previous studies suggest that the incidence of CV 
complications in Japan is not different from that in Europe, 
the United States, or China.
The  Avoiding  Cardiovascular  Events  through 
Combination Therapy in Patients Living with Systolic 
Hypertension (ACCOMPLISH) trial was a double-blind 
trial that randomized 11,506 patients with hypertension 
who were at high risk for CV events to receive treatment 
with either benazepril plus amlodipine or benazepril 
plus hydrochlorothiazide.65 The primary end point was 
the composite of death from CV causes, nonfatal MI, 
non-fatal stroke, hospitalization for angina, resuscitation 
after sudden cardiac arrest, and coronary revascularization. 
The average blood pressures after dose adjustment were 
131.6/73.3 mmHg in the benazepril–amlodipine group and 
132.5/74.4 mmHg in the benazepril–hydrochlorothiazide 
group. There were 552 primary-outcome events in the 
benazepril–amlodipine group (9.6%) and 679 in the 
benazepril–hydrochlorothiazide group (11.8%). This 
represented an absolute risk reduction of 2.2% with 
benazepril–amlodipine and a relative risk reduction of 
19.6% (95% confidence interval [CI]: 0.72–0.90; p  0.001). 
Authors discuss the superiority of amlodipine when 
compared to hydrochlorothiazide in reducing CV events in 
this trial. This differs from ALLHAT results, which showed 
no difference in event rate when comparing CCB and thiazide 
diuretic. Critics suggest that the difference in outcomes 
may be due to the fact that ALLHAT used chlorthalidone, 
which has double the potency and a longer duration of action 
compared to hydrochlorothiazide.66 It is also noted that the 
combination of CCB with a drug that inhibits the renin-
angiotensin system may offer unique benefits when compared 
to the CCB monotherapy that was utilized in ALLHAT.66
Hosoda et al report that the risk of death in patients with 
CAD receiving secondary prevention therapy is 20 times 
as high as that in healthy individuals.67 Clinicians utilize 
statins, aspirin, and antihypertensives to alleviate this risk 
of death and reduce morbidity in efforts to sustain a reason-
ably good quality of life. In this review, we are charged 
with investigating nifedipine GITS and its role in the treat-
ment of hypertension in high risk patients with CAD. Four 
major studies (INSIGHT, ACTION, STONE, JMIC-B) that 
evaluated the use of nifedipine concluded that nifedipine 
GITS is not inferior to other antihypertensives in reducing 
CV events (Table 1).29,31,39,41 However, when compared to 
diuretics and ACE-Is, nifedipine slowed the progression 
of coronary atherosclerosis and reduced the development 
of new lesions. Yet, clinically this did not translate into a 
reduction of morbidity and mortality. More importantly, we 
recognize the fewer hospitalizations for unstable angina and 
revascularizations given nifedipine’s potential for improved 
symptom control leading to a reduction in patients seeking 
medical care, and hence hospitalizations and procedures. 
The review of trials that included other DHP CCBs, lead 
to the same conclusion of non-inferiority of DHP CCBs. In 
most of the studies presented in this review, the trials were 
designed to test single agents. However, other drug treatments 
were often added for blood-pressure control, thus creating 
confounders and changing the interpretation of the effects of 
the study drug on end points.65 Based on the results of these 
studies, nifedipine GITS may be recommended as add-on 
therapy in patients with CAD to help lower blood pressure 
and possibly improve CV risk. Given that most patients with 
hypertension will require two or more agents for control, nife-
dipine GITS would be an appropriate choice in combination 
therapy. However, the role of nifedipine GITS as first-line 
therapy or as monotherapy in high-risk patients needs to be 
further examined.Vascular Health and Risk Management 2009:5 439
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